{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:20:00Z","timestamp":1789014000477,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,5,4]],"date-time":"2019-05-04T00:00:00Z","timestamp":1556928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,5,4]],"date-time":"2019-05-04T00:00:00Z","timestamp":1556928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Major Technological Innovation Special Project of Hubei Province of China","award":["2018ACA141"],"award-info":[{"award-number":["2018ACA141"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770132"],"award-info":[{"award-number":["81770132"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81873434"],"award-info":[{"award-number":["81873434"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2019,7,1]]},"DOI":"10.1007\/s00277-019-03685-z","type":"journal-article","created":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T10:07:43Z","timestamp":1557137263000},"page":"1721-1732","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":122,"title":["Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy"],"prefix":"10.1007","volume":"98","author":[{"given":"Huiwen","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaohui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisha","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,4]]},"reference":[{"issue":"177","key":"3685_CR1","doi-asserted-by":"publisher","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","volume":"5","author":"RJ Brentjens","year":"2013","unstructured":"Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, Borquez-Ojeda O, Qu J, Wasielewska T, He Q, Bernal Y, Rijo IV, Hedvat C, Kobos R, Curran K, Steinherz P, Jurcic J, Rosenblat T, Maslak P, Frattini M, Sadelain M (2013) CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5(177):177ra38. https:\/\/doi.org\/10.1126\/scitranslmed.3005930","journal-title":"Sci Transl Med"},{"issue":"16","key":"3685_CR2","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, Milone MC, Levine BL, June CH (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368(16):1509\u20131518. https:\/\/doi.org\/10.1056\/NEJMoa1215134","journal-title":"N Engl J Med"},{"issue":"16","key":"3685_CR3","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng ZH, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371(16):1507\u20131517. https:\/\/doi.org\/10.1056\/NEJMoa1407222","journal-title":"N Engl J Med"},{"issue":"224","key":"3685_CR4","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, Qu J, Wasielewska T, He Q, Fink M, Shinglot H, Youssif M, Satter M, Wang Y, Hosey J, Quintanilla H, Halton E, Bernal Y, Bouhassira DCG, Arcila ME, Gonen M, Roboz GJ, Maslak P, Douer D, Frattini MG, Giralt S, Sadelain M, Brentjens R (2014) Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6(224):224ra25. https:\/\/doi.org\/10.1126\/scitranslmed.3008226","journal-title":"Sci Transl Med"},{"issue":"9967","key":"3685_CR5","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, Steinberg SM, Stroncek D, Tschemia N, Yuan C, Zhang H, Zhang L, Rosenberg SA, Wayne AS, Mackall CL (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385(9967):517\u2013528. https:\/\/doi.org\/10.1016\/s0140-6736(14)61403-3","journal-title":"Lancet"},{"issue":"6","key":"3685_CR6","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM, Robinson E, Steevens NN, Chaney C, Soma L, Chen XY, Yeung C, Wood B, Li D, Cao JH, Heimfeld S, Jensen MC, Riddell SR, Maloney DG (2016) CD19 CAR-T cells of defined CD4(+): CD8(+) composition in adult B cell ALL patients. J Clin Invest 126(6):2123\u20132138. https:\/\/doi.org\/10.1172\/jci85309","journal-title":"J Clin Invest"},{"issue":"25","key":"3685_CR7","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","volume":"129","author":"RA Gardner","year":"2017","unstructured":"Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, Bleakley M, Brown C, Mgebroff S, Kelly-Spratt KS, Hoglund V, Lindgren C, Oron AP, Li D, Riddell SR, Park JR, Jensen MC (2017) Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood 129(25):3322\u20133331. https:\/\/doi.org\/10.1182\/blood-2017-02-769208","journal-title":"Blood"},{"issue":"5","key":"3685_CR8","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00277-018-3246-4","volume":"97","author":"GQ Wei","year":"2018","unstructured":"Wei GQ, Hu YX, Pu CF, Yu J, Luo Y, Shi JM, Cui Q, Wu WJ, Wang JP, Xiao L, Wu Z, Huang H (2018) CD19 targeted CAR-T therapy versus chemotherapy in re-induction treatment of refractory\/relapsed acute lymphoblastic leukemia: results of a case-controlled study. Ann Hematol 97(5):781\u2013789. https:\/\/doi.org\/10.1007\/s00277-018-3246-4","journal-title":"Ann Hematol"},{"issue":"5","key":"3685_CR9","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Riviere I, Gonen M, Wang X, Senechal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E, Roshal M, Maslak P, Davila M, Brentjens RJ, Sadelain M (2018) Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 378(5):449\u2013459. https:\/\/doi.org\/10.1056\/NEJMoa1709919","journal-title":"N Engl J Med"},{"issue":"1","key":"3685_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13045-018-0572-x","volume":"11","author":"J Weng","year":"2018","unstructured":"Weng J, Lai P, Qin L, Lai Y, Jiang Z, Luo C, Huang X, Wu S, Shao D, Deng C, Huang L, Lu Z, Zhou M, Zeng L, Chen D, Wang Y, Chen X, Geng S, Robert W, Tang Z, He C, Li P, Du X (2018) A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia. J Hematol Oncol 11(1):25. https:\/\/doi.org\/10.1186\/s13045-018-0572-x","journal-title":"J Hematol Oncol"},{"issue":"4","key":"3685_CR11","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.ymthe.2018.01.022","volume":"26","author":"Z Cheng","year":"2018","unstructured":"Cheng Z, Wei RH, Ma QL, Shi L, He F, Shi ZX, Jin T, Xie RL, Wei BF, Chen J, Fang HL, Han XL, Rohrs JA, Bryson P, Liu YR, Li QJ, Zhu B, Wang P (2018) In vivo expansion and antitumor activity of Coinfused CD28-and 4-1BB-engineered CAR-T cells in patients with B cell leukemia. Mol Ther 26(4):976\u2013985. https:\/\/doi.org\/10.1016\/j.ymthe.2018.01.022","journal-title":"Mol Ther"},{"issue":"3","key":"3685_CR12","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/bjh.15195","volume":"181","author":"SQ Li","year":"2018","unstructured":"Li SQ, Zhang JS, Wang ML, Fu G, Li YY, Pei L, Xiong ZX, Qin DB, Zhang R, Tian XB, Wei ZH, Chen R, Chen XJ, Wan J, Chen J, Wei X, Xu YM, Zhang P, Wang P, Peng X, Yang SN, Shen JJ, Yang Z, Chen JP, Qian C (2018) Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB. Br J Haematol 181(3):360\u2013371. https:\/\/doi.org\/10.1111\/bjh.15195","journal-title":"Br J Haematol"},{"issue":"12","key":"3685_CR13","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","volume":"119","author":"JN Kochenderfer","year":"2012","unstructured":"Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan D-AN, Morgan RA, Laurencot C, Rosenberg SA (2012) B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119(12):2709\u20132720. https:\/\/doi.org\/10.1182\/blood-2011-10-384388","journal-title":"Blood"},{"issue":"17","key":"3685_CR14","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1182\/blood-2011-10-387969","volume":"119","author":"BG Till","year":"2012","unstructured":"Till BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG, Lindgren CG, Lin Y, Pagel JM, Budde LE, Raubitschek A, Forman SJ, Greenberg PD, Riddell SR, Press OW (2012) CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 119(17):3940\u20133950. https:\/\/doi.org\/10.1182\/blood-2011-10-387969","journal-title":"Blood"},{"issue":"2","key":"3685_CR15","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.clim.2014.10.002","volume":"155","author":"Y Wang","year":"2014","unstructured":"Wang Y, W-y Z, Q-w H, Liu Y, H-r D, Y-l G, Bo J, Fan H, Zhang Y, Y-j Z, M-x C, K-c F, Q-s W, X-b F, W-d H (2014) Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. Clin Immunol 155(2):160\u2013175. https:\/\/doi.org\/10.1016\/j.clim.2014.10.002","journal-title":"Clin Immunol"},{"issue":"6","key":"3685_CR16","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","volume":"33","author":"JN Kochenderfer","year":"2015","unstructured":"Kochenderfer JN, Dudley ME, Kassim SH, Somerville RPT, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, Raffeld M, Feldman S, Lu L, Li YF, Ngo LT, Goy A, Feldman T, Spaner DE, Wang ML, Chen CC, Kranick SM, Nath A, Nathan D-AN, Morton KE, Toomey MA, Rosenberg SA (2015) Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 33(6):540\u2013U531. https:\/\/doi.org\/10.1200\/jco.2014.56.2025","journal-title":"J Clin Oncol"},{"issue":"355","key":"3685_CR17","doi-asserted-by":"publisher","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","volume":"8","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi LA, Berger C, Hudecek M, Pender B, Robinson E, Hawkins R, Chaney C, Cherian S, Chen X, Soma L, Wood B, Li D, Heimfeld S, Riddell SR, Maloney DG (2016) Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med 8(355):355ra116. https:\/\/doi.org\/10.1126\/scitranslmed.aaf8621","journal-title":"Sci Transl Med"},{"issue":"9","key":"3685_CR18","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1172\/JCI86721","volume":"126","author":"P Kebriaei","year":"2016","unstructured":"Kebriaei P, Singh H, Huls MH, Figliola MJ, Bassett R, Olivares S, Jena B, Dawson MJ, Kumaresan PR, Su SH, Maiti S, Dai JL, Moriarity B, Forget MA, Senyukov V, Orozco A, Liu TT, McCarty J, Jackson RN, Moyes JS, Rondon G, Qazilbash M, Ciurea S, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Kantarjian H, Keating M, Wierda W, Do KA, Largaespada DA, Lee DA, Hackett PB, Champlin RE, Cooper LJN (2016) Phase I trials using sleeping beauty to generate CD19-specific CAR T cells. J Clin Invest 126(9):3363\u20133376. https:\/\/doi.org\/10.1172\/jci86721","journal-title":"J Clin Invest"},{"issue":"2","key":"3685_CR19","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","volume":"45","author":"JC Fitzgerald","year":"2017","unstructured":"Fitzgerald JC, Weiss SL, Maude SL, Barrett DM, Lacey SF, Melenhorst JJ, Shaw P, Berg RA, June CH, Porter DL, Frey NV, Grupp SA, Teachey DT (2017) Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit Care Med 45(2):e124\u2013e131. https:\/\/doi.org\/10.1097\/ccm.0000000000002053","journal-title":"Crit Care Med"},{"issue":"21","key":"3685_CR20","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","volume":"130","author":"KT Mueller","year":"2017","unstructured":"Mueller KT, Maude SL, Porter DL, Frey N, Wood P, Han X, Waldron E, Chakraborty A, Awasthi R, Levine BL, Melenhorst JJ, Grupp SA, June CH, Lacey SF (2017) Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. Blood 130(21):2317\u20132325. https:\/\/doi.org\/10.1182\/blood-2017-06-786129","journal-title":"Blood"},{"issue":"26","key":"3685_CR21","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY (2017) Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377(26):2531\u20132544. https:\/\/doi.org\/10.1056\/NEJMoa1707447","journal-title":"N Engl J Med"},{"issue":"303","key":"3685_CR22","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","volume":"7","author":"DL Porter","year":"2015","unstructured":"Porter DL, Hwang W-T, Frey NV, Lacey SF, Shaw PA, Loren AW, Bagg A, Marcucci KT, Shen A, Gonzalez V, Ambrose D, Grupp SA, Chew A, Zheng Z, Milone MC, Levine BL, Melenhorst JJ, June CH (2015) Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 7(303):303ra139. https:\/\/doi.org\/10.1126\/scitranslmed.aac5415","journal-title":"Sci Transl Med"},{"issue":"26","key":"3685_CR23","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Kochenderfer JN (2016) Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127(26):3321\u20133330. https:\/\/doi.org\/10.1182\/blood-2016-04-703751","journal-title":"Blood"},{"issue":"6","key":"3685_CR24","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","volume":"6","author":"DT Teachey","year":"2016","unstructured":"Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, Pequignot E, Gonzalez VE, Chen F, Finklestein J, Barrett DM, Weiss SL, Fitzgerald JC, Berg RA, Aplenc R, Callahan C, Rheingold SR, Zheng Z, Rose-John S, White JC, Nazimuddin F, Wertheim G, Levine BL, June CH, Porter DL, Grupp SA (2016) Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov 6(6):664\u2013679. https:\/\/doi.org\/10.1158\/2159-8290.cd-16-0040","journal-title":"Cancer Discov"},{"key":"3685_CR25","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13045-016-0299-5","volume":"9","author":"Y Hu","year":"2016","unstructured":"Hu Y, Sun J, Wu Z, Yu J, Cui Q, Pu C, Liang B, Luo Y, Shi J, Jin A, Xiao L, Huang H (2016) Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy. J Hematol Oncol 9:70. https:\/\/doi.org\/10.1186\/s13045-016-0299-5","journal-title":"J Hematol Oncol"},{"issue":"5","key":"3685_CR26","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/bjh.14680","volume":"181","author":"H Mei","year":"2018","unstructured":"Mei H, Jiang H, Wu Y, Guo T, Xia L, Jin R, Hu Y (2018) Neurological toxicities and coagulation disorders in the cytokine release syndrome during CAR-T therapy. Br J Haematol 181(5):689\u2013692. https:\/\/doi.org\/10.1111\/bjh.14680","journal-title":"Br J Haematol"},{"issue":"1","key":"3685_CR27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ (2018) Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol 15(1):47\u201362. https:\/\/doi.org\/10.1038\/nrclinonc.2017.148","journal-title":"Nat Rev Clin Oncol"},{"issue":"95","key":"3685_CR28","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","volume":"3","author":"M Kalos","year":"2011","unstructured":"Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3(95):95ra73. https:\/\/doi.org\/10.1126\/scitranslmed.3002842","journal-title":"Sci Transl Med"},{"issue":"12","key":"3685_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013904","volume":"6","author":"XY Tang","year":"2016","unstructured":"Tang XY, Sun Y, Zhang A, Hu GL, Cao W, Wang DH, Zhang B, Chen H (2016) Third-generation CD28\/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol. BMJ Open 6(12):e013904. https:\/\/doi.org\/10.1136\/bmjopen-2016-013904","journal-title":"BMJ Open"},{"issue":"1","key":"3685_CR30","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","volume":"131","author":"JA Hill","year":"2018","unstructured":"Hill JA, Li D, Hay KA, Green ML, Cherian S, Chen XY, Riddell SR, Maloney DG, Boeckh M, Turtle CJ (2018) Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood 131(1):121\u2013130. https:\/\/doi.org\/10.1182\/blood-2017-07-793760","journal-title":"Blood"},{"key":"3685_CR31","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/cid\/ciy152","volume":"67","author":"JH Park","year":"2018","unstructured":"Park JH, Romero FA, Taur Y, Sadelain M, Brentjens RJ, Hohl TM, Seo SK (2018) Cytokine release syndrome grade is a predictive marker for infections in relapsed or refractory B-cell all patients treated with CAR T cells. Clin Infect Dis 67:533\u2013540. https:\/\/doi.org\/10.1093\/cid\/ciy152","journal-title":"Clin Infect Dis"},{"issue":"2","key":"3685_CR32","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124(2):188\u2013195. https:\/\/doi.org\/10.1182\/blood-2014-05-552729","journal-title":"Blood"},{"issue":"6","key":"3685_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129170","volume":"10","author":"M Wang","year":"2015","unstructured":"Wang M, Kou H, Deng J, Wang H, Guo T, Mei H, Hu Y (2015) Retrospective evaluation of new Chinese diagnostic scoring system for disseminated intravascular coagulation. PLoS One 10(6):e0129170. https:\/\/doi.org\/10.1371\/journal.pone.0129170","journal-title":"PLoS One"},{"key":"3685_CR34","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.thromres.2018.11.022","volume":"173","author":"L Luo","year":"2018","unstructured":"Luo L, Wu Y, Niu T, Han Y, Feng Y, Ding Q, Huang R, Zhang X, Feng J, Hou M, Peng J, Li Y, Zhou Y, Su L, Yang L, Zhou Z, Xue F, Gu J, Zhu T, Wang X, Deng J, Mei H, Hu Y (2018) A multicenter, prospective evaluation of the Chinese Society of Thrombosis and Hemostasis Scoring System for disseminated intravascular coagulation. Thromb Res 173:131\u2013140. https:\/\/doi.org\/10.1016\/j.thromres.2018.11.022","journal-title":"Thromb Res"},{"issue":"8","key":"3685_CR35","doi-asserted-by":"publisher","first-page":"9057","DOI":"10.1038\/s41598-017-09190-5","volume":"7","author":"YY Wu","year":"2017","unstructured":"Wu YY, Luo LL, Niu T, Han Y, Feng Y, Ding QL, Huang RB, Zhang XH, Feng JM, Hou M, Peng J, Li Y, Zhou YH, Su L, Yang LH, Zhou ZP, Xue F, Gu J, Zhu TN, Wang XM, Deng J, Mei H, Hu Y (2017) Evaluation of the new Chinese disseminated intravascular coagulation scoring system in critically ill patients: a multicenter prospective study. Sci Rep 7(8):9057. https:\/\/doi.org\/10.1038\/s41598-017-09190-5","journal-title":"Sci Rep"},{"issue":"25","key":"3685_CR36","doi-asserted-by":"crossref","first-page":"17183","DOI":"10.1016\/S0021-9258(17)32538-3","volume":"269","author":"A Goldberger","year":"1994","unstructured":"Goldberger A, Middleton KA, Oliver JA, Paddock C, Yan H-C, Delisser HM, Albelda SM, Newman PJ (1994) Biosynthesis and processing of the cell adhesion molecule PECAM-1 includes production of a soluble form. J Biol Chem 269(25):17183\u201317191","journal-title":"J Biol Chem"},{"issue":"3","key":"3685_CR37","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00441-013-1779-3","volume":"355","author":"JR Privratsky","year":"2014","unstructured":"Privratsky JR, Newman PJ (2014) PECAM-1: regulator of endothelial junctional integrity. Cell Tissue Res 355(3):607\u2013619. https:\/\/doi.org\/10.1007\/s00441-013-1779-3","journal-title":"Cell Tissue Res"},{"issue":"5","key":"3685_CR38","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1080\/17435390.2018.1461267","volume":"12","author":"J Duan","year":"2018","unstructured":"Duan J, Liang S, Yu Y, Li Y, Wang L, Wu Z, Chen Y, Miller MR, Sun Z (2018) Inflammation-coagulation response and thrombotic effects induced by silica nanoparticles in zebrafish embryos. Nanotoxicology 12(5):470\u2013484. https:\/\/doi.org\/10.1080\/17435390.2018.1461267","journal-title":"Nanotoxicology"},{"issue":"12","key":"3685_CR39","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, Yeung C, Liles WC, Wurfel M, Lopez JA, Chen JM, Chung D, Harju-Baker S, Tzpolat T, Fink KR, Riddell SR, Maloney DG, Turtle CJ (2017) Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov 7(12):1404\u20131419. https:\/\/doi.org\/10.1158\/2159-8290.cd-17-0698","journal-title":"Cancer Discov"},{"issue":"21","key":"3685_CR40","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM, Lopez JA, Chen J, Chung D, Harju-Baker S, Cherian S, Chen X, Riddell SR, Maloney DG, Turtle CJ (2017) Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 130(21):2295\u20132306. https:\/\/doi.org\/10.1182\/blood-2017-06-793141","journal-title":"Blood"},{"issue":"3","key":"3685_CR41","first-page":"127","volume":"33","author":"FB Taylor Jr","year":"1991","unstructured":"Taylor FB Jr, Chang A, Ruf W, Morrissey JH, Hinshaw L, Catlett R, Blick K, Edgington TS (1991) Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 33(3):127\u2013134","journal-title":"Circ Shock"},{"issue":"1","key":"3685_CR42","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1172\/JCI116934","volume":"93","author":"M Levi","year":"1994","unstructured":"Levi M, Ten Cate H, Bauer KA, Van Der Poll T, Edgington TS, Buller HR, Van Deventer SJH, Hack CE, Ten Cate JW, Rosenberg RD (1994) Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 93(1):114\u2013120. https:\/\/doi.org\/10.1172\/jci116934","journal-title":"J Clin Invest"},{"issue":"1","key":"3685_CR43","doi-asserted-by":"publisher","first-page":"H159","DOI":"10.1152\/ajpheart.00500.2004","volume":"288","author":"M Maas","year":"2005","unstructured":"Maas M, Stapleton M, Bergom C, Mattson DL, Newman DK, Newman PJ (2005) Endothelial cell PECAM-1 confers protection against endotoxic shock. Am J Phys Heart Circ Phys 288(1):H159\u2013H164. https:\/\/doi.org\/10.1152\/ajpheart.00500.2004","journal-title":"Am J Phys Heart Circ Phys"},{"key":"3685_CR44","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13045-018-0555-y","volume":"11","author":"D Porter","year":"2018","unstructured":"Porter D, Frey N, Wood PA, Weng YQ, Grupp SA (2018) Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol 11:12. https:\/\/doi.org\/10.1186\/s13045-018-0571-y","journal-title":"J Hematol Oncol"},{"key":"3685_CR45","doi-asserted-by":"publisher","first-page":"S82","DOI":"10.1111\/jth.12977","volume":"13","author":"TJ Gould","year":"2015","unstructured":"Gould TJ, Lysov Z, Liaw PC (2015) Extracellular DNA and histones: double-edged swords in immunothrombosis. J Thromb Haemost 13:S82\u2013S91. https:\/\/doi.org\/10.1111\/jth.12977","journal-title":"J Thromb Haemost"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03685-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-019-03685-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03685-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T01:14:38Z","timestamp":1744161278000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-019-03685-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,4]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7,1]]}},"alternative-id":["3685"],"URL":"https:\/\/doi.org\/10.1007\/s00277-019-03685-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,4]]},"assertion":[{"value":"2 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The medical ethics committee of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology has reviewed the trial protocol and allowed the trial to proceed. All patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"JDong is an employee of Wuhan Sian Medical Technology Co., Ltd. The other authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}